Skip to main content
Helen Lawler, MD, Endocrinology, Aurora, CO

HelenMargaretLawlerMD

Endocrinology • Aurora, CO

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Lawler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lawler's full profile

Already have an account?

  • Office

    12605 E 16th Ave
    # F402
    Aurora, CO 80045
    Phone+1 720-848-0000
    Fax+1 720-848-2653

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Endocrinology, Diabetes, and Metabolism, 2010 - 2013
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 2007 - 2010
  • Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of MedicineClass of 2007

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2010 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Managing the Post-Bariatric Patient: Hypoglycemia, Changes in Beta-Cell Function, and Beyond 
    ENDO 2019 - New Orleans, LA - 3/23/2019
  • Managing the Post-Bariatric Patient: Hypoglycemia, Changes in Beta-Cell Function, and Beyond (Repeat) 
    ENDO 2019 - New Orleans, LA - 3/23/2019

Press Mentions

  • Xeris Pharmaceuticals Announces Positive Findings from the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
    Xeris Pharmaceuticals Announces Positive Findings from the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric SurgeryMay 22nd, 2020

Professional Memberships

Dr. Helen Lawler, Dr. Helen Lawler, MD, Dr. H Lawler, Dr. Helen Margaret Lawler